The purpose of this study is to learn if a medicine called itraconazole changes how the body processes the study medicine (PF-08642534) in healthy adults. This study is seeking healthy participants (men or women) who: * are aged 18 to 65 years of age * are confirmed to be healthy by their medical history and medical tests * have body mass index (BMI) of 16 to 30 kilograms per meter squared * have a total body weight of more than 50 kilograms. Participants will receive single doses of the study medicine (PF-08642534) with and without itraconazole. The total planned time of participation is about 12 weeks. The study consists of: * a screening period of up to 28 days before taking study drug * about 4 weeks of staying in the study clinic * a follow-up contact that will occur 28 to 35 days after taking itraconazole the last time.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
14
Participants will receive a single dose of PF-08642534
Participants will receive itraconazole once daily for 13 days (Day 12 to Day 24)
New Haven Clinical Research Unit
New Haven, Connecticut, United States
PF-08642534 Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Time frame: 0 to 240 hours post-dose
Incidence of treatment-emergent Adverse Events
Time frame: Baseline up to approximately 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.